You can use your existing Medical Independent, MediLearning or PharmacistCPD account to log in.


Medicalindependent.ie is Ireland's only investigative medical news website for doctors, healthcare professionals and anyone with an interest in health issues.

Established in 2010, along with its sister publication The Medical Independent, our stated aim is to investigate and analyse the major issues affecting healthcare and the medical profession in Ireland. The Medical Independent has won a number of awards for its investigative journalism, and its stories are frequently picked up by national digital, broadcast and print media. The Medical Independent is published by GreenCross Publishing.

Address: Top Floor, 111 Rathmines Road Lr, Dublin 6

Tel: 353 (01) 441 0024

GreenCross Publishing is owned by Graham Cooke.


The benefits of registering: only registered users:
  • receive the ecCopy two days prior to the printed edition.
  • have automatic access to our free CPD sites.
  • can partake in our online MCQs.
  • can enter our online sports quiz.

Sign up now for ease of access to The Medical Independent, Ireland’s most frequently published medical newspaper, delivering award-winning news and investigative reporting.

Download the new Mindo app for both IOS & Android.

  • Get notified when a story goes live
  • Access Premium Content
  • Read Offline
 
[the_ad_placement id="main-ldb-public"]
[the_ad_placement id="main-ldb-mobile-public"]

You are reading 1 of 2 free-access articles allowed for 30 days

ICS research head calls for further investigation following major prostate cancer screening study

By Dermot - 04th Dec 2019 | 4 views

The Head of Research for the Irish Cancer Society Dr Robert O’Connor has told this newspaper that further research is required after interim results from a long-term study evaluating the validity of targeted prostate-specific antigen (PSA) screening recommended that all men aged over 40 with the BRCA2 gene mutation are systematically screened for prostate cancer.

Dr Robert O’Connor

Presenting the interim IMPACT trial data at the recent Gathering around Cancer conference in Dublin, Prof Ros Eeles of the Institute of Cancer Research and the Royal Marsden NHS Trust, London, UK, said that their results found that men who carry the BRCA2 gene mutation are at risk of developing aggressive prostate cancer and so should undergo regular PSA testing.

The IMPACT study involved almost 3,000 men from 20 countries who were recruited from families that had carriers of mutations of the BRCA1 and BRCA2 genes and who underwent annual PSA testing and biopsy. Men who carried the BRCA2 mutations were almost twice as likely to develop prostate cancer than were non-carriers.

According to Prof Eeles, every man over the age of 40 who carries a mutation in the BRCA2 gene should be offered an annual PSA test – and it is hoped that this will be recommended in clinical guidelines in the near future.

The European Association of Urology guidelines committee is currently examining the issue.

Commenting on the IMPACT study results to the Medical Independent, Dr O’Connor said, although it has been known for some time that prostate cancer has genetic and familial associations, further study results examining the outcomes of such targeted screening in a real-world setting are required.

“Screening for prostate cancer is complex and not recommended for all men, such as it is for women in breast and cervical cancer,” according to Dr O’Connor.

“General population-level screening should only be carried out when we can do something with the results. This is relatively new research and it can take time for research to be turned into practice. Studies are ongoing currently to test the theory in a real-world setting.”

Leave a Reply

[the_ad_placement id="main-ldb-public-2"]
[the_ad_placement id="main-ldb-mobile-public-2"]
Latest Issue
The Medical Independent – 24 June 2021

You need to be logged in to access this content. Please login or sign up using the links below.

[the_ad_placement id="main-mpu-public"]
Most Read
[the_ad_placement id="main-ldb-public-2"]
[the_ad_placement id="main-ldb-mobile-public-2"]